3,6-二甲基喹唑啉-4-酮 | 1018983-98-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 3,6-二甲基喹唑啉-4-酮
• 英文名称: 3,6-dimethylquinazolin-4(3H)-one
• 英文别名: 3,6-dimethylquinazolin-4-one
• CAS: 1018983-98-6
• 化学式: C₁₀H₁₀N₂O
• mdl: MFCD20257651
• 分子量: 174.202
• InChiKey: BXZIXFZODFTHOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,6-二甲基喹唑啉-4-酮 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 生成 6-(bromomethyl)-3-methylquinazolin-4-one
  参考文献：
  名称：

  Analogues of 4-[(7-Bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methylprop-2-ynylamino]-N-(3-pyridylmethyl)benzamide (CB-30865) as Potent Inhibitors of Nicotinamide Phosphoribosyltransferase (Nampt)

  摘要：

  We have shown previously that the target of the potent cytatoxic agent 4-[(7-bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]-N-(3-pyridylmethyl)benzamide (CB38065, 1) is nicotinamide phosphoribosyltransferase (Nampt). With its cellular target known we sought to optimize the biochemical and cellular Nampt activity of 1 as well as its cytotoxicity. It was found that a 3-pyridyl-methylamide substituent in the A region was critical to cellular Nampt activity and cytotoxicity, although other aromatic substitution did yield compounds with submicromolar enzymatic inhibition. Small unsaturated groups worked best in the D-region of the molecule, with 3,3-dimethylallyl providing optimal potency. The E region required a quinazolin-4-one or 1,2,3-benzotriazin-4-one group for activity, and many substituents were tolerated at C(2) of the quinazolin-4-one. The best compounds showed subnanomolar inhibition of Nampt and low nanomolar cytotoxicity in cellular assays.

  DOI：

  10.1021/jm101145b
• 作为产物：
  描述：

  2-氨基-5-甲基苯甲酸 在 potassium carbonate 、 caesium carbonate 作用下， 以 乙腈 为溶剂， 反应 5.0h， 生成 3,6-二甲基喹唑啉-4-酮
  参考文献：
  名称：

  一种4-亚甲基-N-羟基苯甲酰胺类化合物及其应用

  摘要：

  本发明属于医药技术领域，涉及一种具有HDAC6抑制活性和抗肿瘤活性的4‑亚甲基‑N‑羟基苯甲酰胺类化合物以及在制备组蛋白去乙酰化酶抑制剂及其在制备用于治疗和/或预防癌症药物中的用途。一种4‑亚甲基‑N‑羟基苯甲酰胺类化合物，化合物为式I或II所示化合物及其药学上可接受的盐或水合物。本发明合成了一系列含有4‑亚甲基‑N‑羟基苯甲酰胺结构的化合物，化合物包含以下片段：吡唑基苯并[d][1,2,3]三氮唑结构片段、吡唑基2‑氨基苯并噻唑结构以片段及吡唑基喹唑啉‑4‑酮结构片段；所得化合物体外酶抑制活性和抗肿瘤活性测试具有优异的HDAC6抑制作用以及良好的抗肿瘤活性。

  公开号：

  CN114621194A

文献信息

• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
  申请人：FOGHORN THERAPEUTICS INC

  公开号：WO2019152437A1

  公开（公告）日：2019-08-08

  The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

  本公开涉及用于治疗BAF复合物相关疾病的化合物。
• [EN] SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT<br/>[FR] IMIDAZOLES SUBSTITUÉS POUR L'INHIBITION DE TGF-BÊTA ET MÉTHODES DE TRAITEMENT
  申请人：CLAVIUS PHARMACEUTICALS LLC

  公开号：WO2020041562A1

  公开（公告）日：2020-02-27

  This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.

  这项披露涉及抑制TGF-b信号通路的低分子量取代咪唑化合物。更具体地，这项披露涉及使用上述咪唑化合物治疗与TGF-b信号通路相关的疾病的方法，包括但不限于动脉粥样硬化、马凡综合征、洛伊斯-迪茨综合征、肥胖症、糖尿病、多发性硬化、圆锥角膜、特发性肺纤维化、阿尔茨海默病、慢性肾病和硬皮病。
• [EN] TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS MODULATEURS DE TLR2, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：AXIAL THERAPEUTICS INC

  公开号：WO2021242923A1

  公开（公告）日：2021-12-02

  The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

  本公开涉及调节Toll样受体（TLR）蛋白活性的化合物，包括激动剂或激活剂、部分激动剂和拮抗剂。特别感兴趣的是调节TLR2活性的化合物，以及使用这些化合物治疗与TLR2通路相关的癌症和其他疾病的方法。
• [EN] INHIBITORS OF HCV NS5A<br/>[FR] INHIBITEURS DE NS5A DU VHC
  申请人：PRESIDIO PHARMACEUTICALS INC

  公开号：WO2011149856A1

  公开（公告）日：2011-12-01

  Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.

  本文提供了一些化合物、药物组合以及联合治疗方案，用于抑制丙型肝炎。
• PLATELET ADP RECEPTOR INHIBITORS
  申请人：SCARBOROUGH ROBERT M.

  公开号：US20080194597A1

  公开（公告）日：2008-08-14

  Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

  化合物的式子(I)到(VIII)，其中更特别地包括磺酰脲衍生物、磺酰硫脲衍生物、磺酰胍衍生物、磺酰氰胍衍生物、硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物，这些衍生物是有效的血小板ADP受体抑制剂。这些衍生物可以用于各种制药组合物中，特别是对于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病非常有效。本发明还涉及一种预防或治疗哺乳动物血栓形成的方法，包括给予化合物的式子(I)到(VIII)或其药学上可接受的盐的治疗有效量。